此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Thread Embedding Acupuncture Added to Antihistamine Treatment for Chronic Urticaria

2026年11月12日 更新者:Do Thanh Sang、University of Medicine and Pharmacy at Ho Chi Minh City

Evaluation of the Efficacy and Safety of Thread Embedding Acupuncture Combined With an H1 Antihistamine for the Treatment of Chronic Urticaria

This study will test whether adding thread embedding acupuncture to an antihistamine helps adults with chronic hives whose symptoms remain bothersome despite taking the antihistamine. In thread embedding acupuncture, a clinician uses a needle to place a small dissolvable thread at an acupuncture point. The comparison procedure uses the same acupuncture points and a needle, without placing a thread. Both groups take cetirizine.

The researchers plan to enroll 124 adults at three hospitals in Ho Chi Minh City, Vietnam. Participants will be assigned by chance to one of the two groups. They will receive two procedures, two weeks apart. Participants and the people who assess their symptoms will not know which procedure they received. The main assessment compares changes in hives and itching after four weeks. The study will also assess quality of life, a blood marker called total immunoglobulin E, additional antihistamine use, side effects, and whether symptoms return during follow-up through week 8.

研究概览

详细说明

This multicenter, randomized, sham-controlled, parallel-group trial compares polydioxanone (PDO) thread embedding acupuncture plus cetirizine with sham thread embedding acupuncture plus cetirizine. Eligible adults will complete a 7-day run-in with oral cetirizine 10 mg daily and a daily hives and itch diary. Participants with a 7-day Urticaria Activity Score (UAS7) of at least 16 and a weekly itch score of at least 8 after run-in are eligible for randomization.

The trial plans to randomize 124 participants in a 1:1 ratio using concealed block randomization through REDCap. Participants and outcome assessors are masked to allocation. The statistician will analyze coded groups. Clinicians performing the procedure know the assignment. Procedures are scheduled at baseline and week 2, with a 4-week treatment period and a further 4 weeks of follow-up. The primary analysis compares change from baseline in UAS7 at week 4. Other assessments include UAS7 at weeks 2 and 8, urticaria-related quality of life, serum total IgE, rescue medication use, adverse events, and symptom recurrence. Analyses are planned on an intention-to-treat basis.

研究类型

介入性

注册 (估计的)

124

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Sang Thanh Do, MD, MSc
  • 电话号码:+84 948 561 030
  • 邮箱:dtsang@ump.edu.vn

学习地点

      • Ho Chi Minh City、越南
        • Ho Chi Minh City Traditional Medicine Hospital, Outpatient Department
      • Ho Chi Minh City、越南
        • Le Van Thinh Hospital, Department of Dermatology
      • Ho Chi Minh City、越南
        • University Medical Center Ho Chi Minh City, Branch 3

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 18 years or older and willing to provide written informed consent.
  • Chronic urticaria diagnosed according to the EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline. Transient wheals and itching occur at least daily for more than 6 weeks despite prior or current use of an H1 antihistamine, without serious systemic symptoms. Individual wheals resolve within 30 minutes to 24 hours.
  • UAS7 of at least 16 and weekly itch score of at least 8 after the 7-day run-in.
  • No previous thread embedding acupuncture.

Exclusion Criteria:

  • Urticaria with an identified cause, including physical or mechanical urticaria.
  • Warning signs of systemic or autoinflammatory disease (e.g., Schnitzler syndrome or cryopyrin-associated periodic syndromes), or urticarial vasculitis.
  • Cutaneous mast cell disease or erythema multiforme.
  • Current or prior severe associated symptoms such as laryngeal edema, acute angioedema, anaphylaxis, or bradykinin-mediated angioedema including hereditary angioedema.
  • Other chronic pruritic skin disease that could interfere with assessment.
  • History of allergy to implant materials, especially absorbable suture or catgut, or a predisposition to keloid formation.
  • Current or recent immunosuppressive therapy or systemic corticosteroids within 2 to 4 weeks (or 30 days) before participation, as specified in the protocol.
  • Biologics such as omalizumab, leukotriene receptor antagonists, or H2 antihistamines within 7 to 14 days before screening or randomization, as specified in the protocol.
  • H1 antihistamine use above the recommended dose within 3 days before screening.
  • Psychotropic medication within the preceding month.
  • Malignancy or severe endocrine disorder.
  • Serious cardiovascular or cerebrovascular disease, diabetes mellitus, severe hepatic or renal failure, or a hematopoietic disorder.
  • Severe debilitation with reduced immune resistance.
  • Other serious systemic autoimmune disease, such as systemic lupus erythematosus.
  • Cognitive impairment, psychiatric illness, or a communication barrier that prevents participation in the treatment procedures.
  • A nonabsorbable implant at the intended procedure site.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study.
  • Participation in another clinical trial in the preceding 3 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:PDO Thread Embedding Acupuncture Plus Cetirizine

Participants receive polydioxanone (PDO) thread embedding acupuncture at baseline and week 2, plus oral cetirizine as background treatment.

An absorbable monofilament polydioxanone (PDO) thread is implanted at seven bilateral acupuncture points (14 sites) at baseline and week 2.

Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

假比较器:Sham Thread Embedding Acupuncture Plus Cetirizine

Participants receive a sham procedure at the same acupuncture points at baseline and week 2. The clinician uses an empty needle, so no thread is implanted. Participants also receive oral cetirizine as background treatment.

Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

The clinician inserts and withdraws an empty needle at the same acupuncture points at baseline and week 2. The procedure leaves no implanted thread.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in 7-Day Urticaria Activity Score (UAS7) at Week 4
大体时间:Baseline and week 4

UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

Baseline and week 4

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in UAS7 at Weeks 2 and 8
大体时间:Baseline and weeks 2 and 8

UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

Baseline and weeks 2 and 8
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score
大体时间:Baseline and weeks 2, 4, and 8

Participants complete the disease-specific questionnaire about how chronic urticaria affected their lives in the preceding two weeks. Higher scores indicate greater impairment. Change is calculated as the follow-up score minus baseline.

Baseline and weeks 2, 4, and 8
Change From Baseline in Serum Total Immunoglobulin E (IgE)
大体时间:Baseline and week 4

Serum total IgE is measured by enzyme-linked immunosorbent assay (ELISA) and reported in IU/mL. Change is calculated as the week 4 concentration minus baseline.

Baseline and week 4
Proportion of Participants With Adverse Events
大体时间:From baseline through week 8

The study records adverse events and serious adverse events in each group during treatment and follow-up. Event severity is graded using the protocol-specified CTCAE criteria.

From baseline through week 8
Proportion of Participants Reporting Recurrence or Flare of Urticaria Symptoms
大体时间:Weeks 4 through 8

Participants are contacted by telephone at week 8 using a standardized script to determine whether symptoms returned or flared during the post-treatment follow-up.

Weeks 4 through 8
Number of Rescue Cetirizine Tablets Used
大体时间:From baseline through week 4

The total number of additional cetirizine tablets taken for symptom relief beyond the scheduled background dose is compared between groups.

From baseline through week 4

其他结果措施

结果测量
措施说明
大体时间
Association of Baseline UAS7, Serum Total IgE, and Disease Duration With UAS7 at Week 4
大体时间:Baseline and week 4

A multivariable linear regression will estimate the association of each baseline factor with week 4 UAS7, adjusting for study group and site.

Baseline and week 4

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sang Thanh Do, MD, MSc、University of Medicine and Pharmacy at Ho Chi Minh City

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年7月1日

初级完成 (估计的)

2029年2月1日

研究完成 (估计的)

2029年3月1日

研究注册日期

首次提交

2026年11月12日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅